---
schema_version: "secwatch.filing_event.v1"
accession: "0000816956-26-000006"
form_type: "8-K"
ticker: "CNMD"
cik: "0000816956"
company_name: "CONMED Corp"
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T07:15:18.057724+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS

## Summary
- Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
- FY2025 sales $1.3747B (+5.2%); GAAP EPS $1.51 vs $4.25, adjusted EPS $4.59 vs $4.17.
- FY2026 guidance: revenue $1.345B-$1.375B (organic constant-currency growth 4.5%-6% ex-gastro), adj. EPS $4.30-$4.45.
- International Q4 revenue +17% (reported) vs domestic +1.4%; Orthopedic Surgery segment +13.2%.
- GAAP results weighed by ~$60M in Q4 operating charges including optimization and product rationalization.

## SEC filing metadata
- accession: 0000816956-26-000006
- form_type: 8-K
- ticker: CNMD
- cik: 0000816956
- company_name: CONMED Corp
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/816956/000081695626000006/0000816956-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/816956/000081695626000006/cnmd-20260128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000816956-26-000006
- JSON: https://secwatch.observer/filing/0000816956-26-000006.json
- Plain text: https://secwatch.observer/filing/0000816956-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.